Aussie Pharma Biota Fortunes Rise On Relenza As Swine Flu Drug
This article was originally published in PharmAsia News
Executive Summary
Australia's Biota Holdings stands to be a big winner as most of the world takes steps to block a possible pandemic of swine flu, which has two main treatments, one of them Biota's Relenza (zanamivir). Similarly, sales of Tamiflu (oseltamivir) already are rising For Roche and its inventor, U.S.-based Gilead. Biota developed the Relenza anti-viral, which it manufactures in Australia and licenses to GlaxoSmithKline of the United Kingdom. Both drugs have been shown to be effective against the fast-spreading swine flu the World Health Organization warns could develop into a global pandemic. (Click here for more